Close Menu

IntegraGen

Belgium's OncoDNA believes that IntegraGen's bioinformatics platform will help it manage more cancer patient data and quickly generate patient-specific treatment reports for clinicians.

Belgium-based OncoDNA will purchase France's IntegraGen as part of its plans to provide a solution that combines oncology laboratory testing and bioinformatics software.

The French bioinformatics and genomic services company will help Dana-Farber manage clinical research data for the cancer center's new interpretive genomics program. 

The launch of the sequencing platforms is a milestone for the Plan France Médecine Génomique 2025, a €670 million initiative the French government announced two years ago.

GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.

The test, miRpredX 31-3p, is a positive theranostic test that quantifies the expression of miR-31-3p in FFPE using RT-qPCR technology. 

Laboratoire Cerba was granted the right to develop a tumor expression test based on IntegraGen's proprietary microRNA biomarker.

The planned sequencing platform will be used for both exome and whole-genome sequencing research projects in the fields of cancer, rare diseases, microbiology, and potentially psychiatry.

The company will work with the investigators to examine whether levels of the microRNA can predict patient outcomes to different anti-EGRF therapies.

The hospital will use the new methods with jointly developed bioinformatic analysis techniques to rapidly interpret genomic data. 

Pages

Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.